Canertinib HCl - CAS# 289499-45-2 60273 1]heptan-2-yl)prop-2-en-1-one

1]heptan-2-yl)prop-2-en-1-one

3T3 fibroblasts

and metabolism

HSP90 or the 53 kinases tested

Palmitic acid suppresses apolipoprotein M gene expression via the pathway of PPARβ/δ in HepG2 cells

Canertinib HCl - CAS# 289499-45-2 60273 1]heptan-2-yl)prop-2-en-1-oneCanertinib, also known as CI1033 and PD183805, CAS No. 289499 45 2, is a potent ErbB inhibitor for the treatment of cancer. It is an irreversible tyrosine kinase inhibitor with activity against EGFR (IC50 0. 8 nM), HER 2 (IC50 19 nM) and ErbB 4 (IC50 7 nM). By 2015, Pfizer had discontinued development of the drug. Canertinib has been reported as a substrate for OATP1B3. Interaction of canertinib with OATP1B3 may alter its hepatic disposition and can